CONTEXT: Inflammation in the pancreas can cause β-cell stress, leading to diabetes development. Access to human pancreas tissues via the Network for Pancreatic Organ Donors with Diabetes (nPOD) has allowed characterization of pathways leading to this inflammation. OBJECTIVE: 12-Lipoxygenase (12-LO) induces inflammation and has been implicated in diabetes development. Our goal was to determine expression of 12-LO in human islets from control, autoantibody-positive, type 1 diabetic, and type 2 diabetic nPOD pancreas donors. DESIGN: Pancreas tissues from nPOD donors were examined by immunohistochemistry and immunofluorescence for islet expression of 12-LO in different subsets of islet cells. PARTICIPANTS: Donor pancreas samples were obtained from nPOD based on disease status (control, n = 7; autoantibody-positive, n = 8; type 1 diabetic, n = 17; or type 2 diabetic donors, n = 15). MAIN OUTCOME MEASURE: Determination of 12-LO expression within human islets served as the main outcome measure, including distinguishing which types of islet cells expressed 12-LO. RESULTS: Islets from control participants (nondiabetic) lacked islet expression of 12-LO. Of donors in the other groups, 25% to 37% expressed islet 12-LO with a clear inverse relation between the numbers of β-cells and 12-LO(+) cells within islets of 12-LO(+) cases. 12-LO expression was not seen within macrophages, endothelial cells, α-cells, or β-cells, but only within cells expressing low levels of pancreatic polypeptide (PP) and increased levels of vimentin. CONCLUSIONS: 12-LO expression colocalizes within a specific type of islet PP(+) cell under prediabetic and diabetic conditions. The costaining of PP and vimentin suggests that 12-LO participates in the process leading to β-cell dedifferentiation in the islet.
CONTEXT: Inflammation in the pancreas can cause β-cell stress, leading to diabetes development. Access to human pancreas tissues via the Network for Pancreatic Organ Donors with Diabetes (nPOD) has allowed characterization of pathways leading to this inflammation. OBJECTIVE: 12-Lipoxygenase (12-LO) induces inflammation and has been implicated in diabetes development. Our goal was to determine expression of 12-LO in human islets from control, autoantibody-positive, type 1 diabetic, and type 2 diabetic nPOD pancreas donors. DESIGN: Pancreas tissues from nPOD donors were examined by immunohistochemistry and immunofluorescence for islet expression of 12-LO in different subsets of islet cells. PARTICIPANTS: Donor pancreas samples were obtained from nPOD based on disease status (control, n = 7; autoantibody-positive, n = 8; type 1 diabetic, n = 17; or type 2 diabetic donors, n = 15). MAIN OUTCOME MEASURE: Determination of 12-LO expression within human islets served as the main outcome measure, including distinguishing which types of islet cells expressed 12-LO. RESULTS: Islets from control participants (nondiabetic) lacked islet expression of 12-LO. Of donors in the other groups, 25% to 37% expressed islet 12-LO with a clear inverse relation between the numbers of β-cells and 12-LO(+) cells within islets of 12-LO(+) cases. 12-LO expression was not seen within macrophages, endothelial cells, α-cells, or β-cells, but only within cells expressing low levels of pancreatic polypeptide (PP) and increased levels of vimentin. CONCLUSIONS: 12-LO expression colocalizes within a specific type of islet PP(+) cell under prediabetic and diabetic conditions. The costaining of PP and vimentin suggests that 12-LO participates in the process leading to β-cell dedifferentiation in the islet.
Authors: Anca D Dobrian; David C Lieb; Banumathi K Cole; David A Taylor-Fishwick; Swarup K Chakrabarti; Jerry L Nadler Journal: Prog Lipid Res Date: 2010-10-21 Impact factor: 16.195
Authors: Banumathi K Cole; Norine S Kuhn; Shamina M Green-Mitchell; Kendall A Leone; Rebekah M Raab; Jerry L Nadler; Swarup K Chakrabarti Journal: Am J Physiol Endocrinol Metab Date: 2012-01-03 Impact factor: 4.310
Authors: D A Taylor-Fishwick; J R Weaver; W Grzesik; S Chakrabarti; S Green-Mitchell; Y Imai; N Kuhn; J L Nadler Journal: Diabetologia Date: 2012-10-03 Impact factor: 10.122
Authors: Jessica R Weaver; Theodore R Holman; Yumi Imai; Ajit Jadhav; Victor Kenyon; David J Maloney; Jerry L Nadler; Ganesha Rai; Anton Simeonov; David A Taylor-Fishwick Journal: Mol Cell Endocrinol Date: 2012-03-20 Impact factor: 4.102
Authors: Shamina M Green-Mitchell; Sarah A Tersey; Banumathi K Cole; Kaiwen Ma; Norine S Kuhn; Tina Duong Cunningham; Nelly A Maybee; Swarup K Chakrabarti; Marcia McDuffie; David A Taylor-Fishwick; Raghavendra G Mirmira; Jerry L Nadler; Margaret A Morris Journal: PLoS One Date: 2013-02-21 Impact factor: 3.240
Authors: Sarah A Tersey; Yurika Nishiki; Andrew T Templin; Susanne M Cabrera; Natalie D Stull; Stephanie C Colvin; Carmella Evans-Molina; Jenna L Rickus; Bernhard Maier; Raghavendra G Mirmira Journal: Diabetes Date: 2012-04 Impact factor: 9.461
Authors: Yumi Imai; Anca D Dobrian; Margaret A Morris; David A Taylor-Fishwick; Jerry L Nadler Journal: Diabetologia Date: 2016-02-11 Impact factor: 10.122
Authors: Kaiwen Ma; An Xiao; So Hyun Park; Lindsey Glenn; Laura Jackson; Tatvam Barot; Jessica R Weaver; David A Taylor-Fishwick; Diane K Luci; David J Maloney; Raghavendra G Mirmira; Yumi Imai; Jerry L Nadler Journal: J Clin Endocrinol Metab Date: 2017-08-01 Impact factor: 5.958
Authors: Sarah A Tersey; Esther Bolanis; Theodore R Holman; David J Maloney; Jerry L Nadler; Raghavendra G Mirmira Journal: Mol Endocrinol Date: 2015-03-24
Authors: Jason W Ashley; William D Hancock; Alexander J Nelson; Robert N Bone; Hubert M Tse; Mary Wohltmann; John Turk; Sasanka Ramanadham Journal: J Biol Chem Date: 2016-09-20 Impact factor: 5.157
Authors: A D Dobrian; M A Morris; D A Taylor-Fishwick; T R Holman; Y Imai; R G Mirmira; J L Nadler Journal: Pharmacol Ther Date: 2018-10-19 Impact factor: 12.310
Authors: Tanya C Burch; Margaret A Morris; Martha Campbell-Thompson; Alberto Pugliese; Jerry L Nadler; Julius O Nyalwidhe Journal: PLoS One Date: 2015-08-24 Impact factor: 3.240